TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06413433: A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)

Sponsor: Axsome Therapeutics, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 450 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,890,264

Rescue Site Savings

+$7,165,888

Unlock Full NCT06413433 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06413433 Rescue Dossier →